The traditional timeline for designing a personalized cancer treatment was measured in months or years. AI is compressing that timeline to weeks — and in some steps, to minutes.
Google DeepMind's AlphaFold solved one of biology's oldest problems: predicting how a protein folds into its 3D shape from its amino acid sequence. This used to take months of laboratory work per protein. AlphaFold does it in minutes. For cancer vaccine design, this means rapidly predicting which tumor mutations produce proteins that are actually visible to the immune system.
Machine learning models now predict which tumor mutations will produce effective neoantigens — protein fragments that trigger an immune response. These models analyze thousands of features simultaneously: mutation type, protein structure, MHC binding affinity, expression levels, and clonality. What used to require expert immunologists working for weeks now takes algorithms hours.
AI models predict how strongly each candidate neoantigen will bind to a specific patient's MHC molecules. This step is critical because only neoantigens that bind well to your MHC will be displayed on cell surfaces where your immune system can see them. AI makes this patient-specific prediction possible at scale.
AI has compressed the computational steps dramatically. The remaining bottleneck is biological: manufacturing the actual mRNA vaccine and administering it. But even here, production time has dropped from nine weeks to under four. The future of personalized cancer medicine is fast — and it all starts with having your genome data ready.
Related: mRNA Cancer Vaccines in 2026 · MHC Typing Explained · View Pricing
Ready to secure your genome?
Join the Waitlist